top of page


Third Rock Ventures signs AI antibody discovery partnership with Funnel Biosciences worth up to $2.16 billion
Third Rock Ventures has entered a potentially $2.16 billion AI-enabled antibody discovery collaboration with China's Funnel Biosciences, combining epitope-guided molecular design with multiple venture-selected drug targets.

nuaxia
6 days ago2 min read


Anthropic acquires Mithril Medicine and expands AI-driven drug discovery partnerships
Anthropic has acquired Mithril Medicine and established multiple life sciences research collaborations, moving beyond AI tools into direct participation in experimental drug discovery.

nuaxia
Oct 302 min read


OpenAI acquires Orchestra Bio to expand AI-powered drug development capabilities
OpenAI has acquired Orchestra Bio to strengthen its life-sciences AI capabilities and develop agent-based workflows for pharmaceutical research and development.

nuaxia
Oct 222 min read


Astellas signs AI Proteins miniprotein therapeutics collaboration valued at more than $400 million
Astellas Pharma and AI Proteins have signed a research and licensing agreement worth more than $400 million in potential value to develop novel miniprotein therapeutics.

nuaxia
Oct 222 min read


Eli Lilly partners with METiS TechBio in AI-driven lipid nanoparticle collaboration worth up to $1.1 billion in milestones
Eli Lilly and METiS TechBio have entered an AI-enabled lipid nanoparticle discovery collaboration carrying up to approximately $1.1 billion in potential milestone payments.

nuaxia
Oct 212 min read


Biodesix partners with Vanderbilt to develop AI-enabled lung nodule diagnostics combining imaging and blood biomarkers
Biodesix is collaborating with Vanderbilt University and Vanderbilt Health to develop an AI-enabled lung nodule risk assessment test combining imaging and blood-based biomarkers.

nuaxia
Oct 202 min read


AstraZeneca signs $1.5 billion AI drug discovery collaboration with insitro for cardiometabolic diseases
AstraZeneca and insitro have entered a $1.5 billion AI-enabled drug discovery collaboration targeting difficult-to-treat cardiometabolic diseases.

nuaxia
Oct 162 min read


Zealand Pharma signs AI protein therapeutics collaboration with Generate Biomedicines worth over $1 billion
Zealand Pharma and Generate Biomedicines have signed an AI-enabled protein therapeutics collaboration for obesity and metabolic diseases with potential milestone payments approaching $1.2 billion.

nuaxia
Oct 152 min read


GSK expands AI drug discovery collaboration with Chai Discovery following successful laboratory evaluation
GSK has expanded its collaboration with Chai Discovery to apply AI-powered protein modelling and molecular design tools across pharmaceutical drug discovery following successful laboratory validation.

nuaxia
Oct 142 min read


Arcturus Therapeutics agrees acquisition of AI drug-discovery company myNEO
Arcturus Therapeutics has agreed to acquire Belgian AI drug-discovery company myNEO, expanding its computational capabilities for mRNA medicine design and target identification.

nuaxia
Sep 252 min read


Boehringer Ingelheim and Envisagenics sign oncology collaboration worth more than $1bn
Boehringer Ingelheim and Envisagenics have entered a multi-year oncology collaboration worth more than $1 billion to discover therapeutic targets created by alternative RNA splicing.

nuaxia
Sep 232 min read


AbbVie and Iambic enter AI-driven drug discovery collaboration across immunology, neuroscience and oncology
AbbVie and Iambic have entered a multi-year collaboration to use artificial intelligence and computational drug discovery across immunology, neuroscience and oncology.

nuaxia
Sep 222 min read


Novo Nordisk and Orbis Medicines sign macrocycle discovery deal worth up to $1.4bn
Novo Nordisk and Orbis Medicines have entered a multi-target drug-discovery partnership worth up to $1.4 billion to develop orally bioavailable macrocycle medicines for cardiometabolic disease.

nuaxia
Sep 182 min read


UK commission sets out new regulatory blueprint for AI in healthcare
A UK national commission has proposed a new regulatory framework for artificial intelligence in healthcare designed to support faster adoption while maintaining safety, accountability and public trust.

nuaxia
Sep 112 min read


Cureety acquires Reimagine Care to expand precision oncology platform
The acquisition combines Cureety's therapy-specific oncology monitoring platform with Reimagine Care's AI-enabled virtual cancer-care capabilities.

nuaxia
Sep 42 min read


Qualcomm and ASUS launch pharmacy AI programme across southern Taiwan
Qualcomm and ASUS have launched an on-premises AI assistant programme for community pharmacies across southern Taiwan.

nuaxia
Sep 32 min read


Monod Bio licenses AI-designed protein technologies to SignalChem for drug discovery assays
The non-exclusive agreement gives SignalChem access to Monod Bio’s LuxSit luciferase and NovoBodies technologies for custom research assays and protein-fusion services, extending the commercial reach of its AI-designed protein platform.

nuaxia
Aug 273 min read


FDA seeks public feedback on regulatory approach for generative AI-enabled medical devices
The discussion paper launches a public consultation that could shape future regulatory expectations for AI-enabled medical devices, including premarket evaluation, risk assessment and postmarket monitoring.

nuaxia
Aug 202 min read


Health Canada licenses Light AI’s QuickScan Strep A smartphone software for suspected strep throat assessment
The Canadian authorisation moves Light AI’s AI-enabled throat-image analysis platform from investigational development into its first regulated market, providing healthcare professionals with a software-based tool to support assessment of suspected Group A Streptococcus infection.

nuaxia
Aug 142 min read


Pathos AI licenses first-in-class bispecific ADC JSKN016 from Alphamab Oncology in deal worth up to $4.8 billion
Pathos AI licenses first-in-class bispecific ADC JSKN016 from Alphamab Oncology in deal worth up to $4.8 billion

nuaxia
Aug 62 min read
bottom of page